ST. JOSEPH, Mich.,. July 21 — GeneGo, Inc., the leading systems biology tools company, announced today that they have recently donated 41 canonical pathway maps to the International Society for Interferon and Cytokine Research (www.isicr.org). These maps are constructed from manually curated, experimentally validated biological and chemical pathway interactions. Each map describes multi-step signaling covering the full spectrum of cellular signaling from ligand-receptor interaction through enzymes and scaffold proteins to transcription factors. The donated maps describe the role of interferons and cytokines in the immune response, development (via a variety of growth hormones), cell cycle, apoptosis, survival, cell adhesion and chemotaxis. In addition to creating canonical pathway maps GeneGo’s software analysis tools enable functions such as determining the biological enrichment and representative networks for a gene (or list of genes), associated metabolism and diseases, and therapeutic drugs complete with supportive links to the public domain literature. Additional tools include full interactome analysis and chemical analysis tools to predict metabolites and activity as well as target and related functions.

“The ISICR is very grateful for receiving permission from GeneGo to include these maps in the ISICR slide repository. This repository, available to ISICR members, currently has over 500 slides that members can use for seminars, courses, lectures, etc. The addition of the GeneGo pathways will certainly provide ISICR members with an exceptionally valuable educational tool,” said Howard Young, Past President ISICR.

“We are very pleased to help the ISICR with this contribution,” said Julie Bryant, GeneGo’s VP of Business Development. “GeneGo has nearly 800 pathway maps available for data mining and experimental analysis in MetaCore.”

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo’s flagship product, MetaCore 5.4(TM), assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 5.4(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore.

For more information, please visit the company’s web site at www.genego.com.

SOURCE GeneGo, Inc.